|
BEAM | Beam Therapeutics Inc. |
|
|
BEAM | Beam Therapeutics Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.38 |
| Leverage | 26.32% |
| Market Cap | $ 2.5B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -413.5m |
| Margin | -386.74% |
Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. The company is headquartered in Cambridge, Massachusetts.